INTRODUCTION
Much has been learnt of the epidemiology of hepatitis C virus (HCV) infection as reliable screening tests have been developed over the last 5 years. As many of those infected are sexually active, clinicians are increasingly likely to be asked about the risk of transmission to sexual partners. In this article, I will review the evidence on which appropriate advice should be based.
VIROLOGY AND NATURAL HISTORY OF INFECTION
HCV is an enveloped, single-stranded positivesense RNA virus classified in the family Flaviviridae. A number of sub-types have now been recognized, some of which may be more virulent than others", About 6-8 weeks after infection, approximately 10% ?f patients develop an acute, self-limiting hepatitic illness. Occasional cases of fulminant hepatitis have been reported, but in the main this acute illness carries no Significant morbidity-. The main concern regarding HCV is that over 50% of those infected will develop chronic Infections. As with chronic hepatitis B virus infection, most patients are asymptomatic until late in the disease when they may present with liver failure. It is now recognized hat approximately 20% of patients with HCV infection will ultimately develop cirrhosis, although there is considerable individual variation in the time taken to progress to this complication". A strong aSSOciation between chronic HCV infection and hepatocellular carcinoma has also been demon-strat~d, particularly in the Far East5-8. Concomitant HIV infection may increase the rate of progression for HCV-infected individuals", Hev infection is diagnosed serologically. The first commercial kits for detecting HCV antibodies became available in 1990 10 ,11. Unfortunately, the original ELISA and recombinant immunoblot assay (RIBA-1) gave large numbers of false positive results 12. Modification of this assay (RIBA-2) has proved more accurate with a considerable reduction in the rate of false positives-'. Ideally, all sera positive by RIBA-2 should undergo further testing by polymerase chain reaction (PCR) to detect the 1 presence of HCV genome, which also confirms that the patient is viraemic and hence potentially infective-", Commonly, up to 70% of RIBA-2 positive samples are found to be PCR-positive 15,16. In the remaining cases whose sera are PCR negative, it is unclear whether this represents recovery from acute/chronic infection, remission of chronic infection or lack of sensitivity of the test. Diagnosis of acute HCV infection remains problematic, as anti-HCV may not be detectable for some monthsl".
The only treatment of confirmed benefit in HCV infection is interferon. Given in doses of 3-6 mega units thrice weekly for 6-12 months, remission of chronic active hepatitis is seen in approximately 50% of cases. Unfortunately, in 50% of those successfully treated there will be relapse on cessation of treatment, giving an overall response rate of approximately 25%18-20.
EPIDEMIOLOGY OF HCV INFECTION ,
The major route of infection with HCV is through parenteral injection. Thus, HCV may be transmitted via blood transfusion, although routine screening of donated blood has significantly reduced the rate of infection-l. Those exposed to multiple transfusions, e.g., haemophiliacs, show high rates of infection 22 • 23 • High seroprevalence rates are also seen amongst needle-sharing intravenous drug users (IDU)23-25. Other methods of parenteral exposure, e.g. needle stick injuries amongst health care workers and tattooing, result in lower rates of infection, which are nonetheless imporlant 26 -28 • Vertical transmission of HCV is recognized, although the risk appears to be small in the absence of concomitant HLV intection-". However, there is a need to consider modes of non-parenteral transmission, as studies of community acquired sporadic HCV infection generally show that in 40-50% of cases the source of infection is unknown 30 , 31. 
WHAT ROLE DOES SEXUAL TRANSMISSION PLAY IN THE EPIDEMIOLOGY OF HCV INFECTION?
The epidemiology of sexually transmitted HCV infection has been investigated in two ways, firstly by looking at the sexual partners of those with the infection, and secondly by looking at population groups at risk of other sexually transmitted diseases (SID) e.g, patients attending STO clinics. As in all studies related in HCV, the reliability of the results is dependent upon the accuracy of the test used. One study of 143 sexual partners of IOU using a first generation assay showed that 16 (11%) were HCV antibody positive 32 • However, studies from Western Europe and the United States using RIBA-2 have generally shown prevalence rates of 0-6% (mean 3%) in the sexual partners of HCV infected individuals 25 ,33-36• Reports from Japan have shown higher levels of sexual transmission. For example one study37 showed that 32/176 (18%) of spouses exposed to infection were anti-HCV positive, 14 of whom were also found to be HCV RNA positive. Another Japanese study in which the overall prevalence of infection amongst exposed spouses was 21%, showed that both male-to-female transmission (3 of 25 wives seropositive) and female-to-male transmission (5 of 13 husbands seropositive) were possible 38 • Analysis of viral genome by partial nucleotide sequencing showed that the virus was homologous in 4 of these couples. Although this demonstrates a common source of infection, sexual transmission cannot be assumed, and there is evidence from Japan of transmission of HCV within families that is difficult to explain by either sexual or vertical transmission'".
Turning now to STD clinic attenders, HCVseroprevalence using first generation assays was found to be 7-16% in gay men 23 ,32,40. One Danish cohort study showed that over an 8-year period, the seroprevalence rose from 1.6% to 4.1%, as a result of 3 seroconversions to HCV41. Conflicting results have been obtained using newer assays. A study from SID clinic attenders in the USA showed that no specific sexual behaviour correlated with HCV seropositivity31. On the other hand an Italian study showed an HCV seroprevalence amongst gay men of 2.1%, and amongst heterosexuals of 1.7%, both rates considerably greater than that amongst Italian blood donorsv. These workers also found that HCV-seropositivity was associated with a history of previous STD. Similar seroprevalence rates have been found amongst heterosexual STO clinic attenders in the USA, where one study showed that 25 (4%)of 571non-drug using heterosexuals attending an SID clinic were HCV-positive. There were 17 males and 8 females, and HCV infection was associated with numbers of sexual partners, frequency of sex, anti-HBs and anti-HN-seropositivity43.
Does concomitant HIV infection increase the rate of transmission of HCV? There is certainly anecdotal evidence to support this 32 ,43,44, and a large study of the sexual partners of haemophiIiacs showed HCV transmission in 5/164 partners where the index case was coinfected with HIV and HCV, versus 0/30, where the index case was infected with HCV alone 33 • It is possible that HIV/HCV coinfection might result in higher levels of circulating HCV with a concomitant increase in infectivity45. However, the concept of 'sexual infectivity' remains problematic as to date HCV RNA has been detected infrequently in semen, urine and vaginal secretions 46 -48 • Is HCV sexually transmitted? The answer is yes, although the risk for the generally sexually active population appears to be small. There is no evidence of a greater risk amongst gay men as opposed to heterosexuals. Those at greatest risk are the sexual partners of known HCV-infected individuals, and the risk of transmission appears to be both maleto-female and female-to-male. Outwith the Far East, the lifetime risk is small. Nonetheless even if the risk of infection is low, the subsequent risk of serious liver disease is high, with a 20% lifetime risk of cirrhosis in those infected with HCV. H one assumes for the sake of argument that the lifetime risk of sexual acquisition of HCV is 5%, then the lifetime risk of developing cirrhosis in this population is in the order of 1%. Only patients can decide whether such a risk is acceptable and there is no scope for clinicians to demonstrate dogmatism either for or against the use of barrier methods of contraception. Regular testing of sexual partners should be undertaken whether or not intercourse is protected. This will offer the opportunity to explore further the epidemiology of HCV infection, as well as diagnosing and offering follow-up and treatment to those who may become infected.
